Published in AIDS Weekly, February 13th, 2006
The peptides, TR-291144 and TR-290999, first synthesized at Trimeris, are distinct compounds derived from HR2 sequences of HIV. In connection with this event, Trimeris will receive a payment from Roche.
TR-291144 and TR-290999 are being developed with the specific goal of achieving durable suppression of HIV by increasing the potency of the molecules and raising their genetic barrier to the development of resistance. Also central to the development...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.